DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for cavernous sinus meningioma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCavernous sinus meningioma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cavernous sinus meningioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dihydrofolate reductase (DHFR) — DHFR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4M6J · 1.201 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
Cavernous sinus meningiomas are defined as tumours that either originate within the cavernous sinus or arise from adjacent structures such as the anterior clinoid and inner sphenoid ridge and then invade the sinus. The anatomy of the cavernous sinus is complex because of the high density of critically important neural and vascular structures. Complete resection of these meningiomas has proven difficult and, in many cases, impossible without causing significant morbidity. A 2005 anatomical study of 30 cadaveric specimens noted that a precise understanding of bony relationships and neurovascular contents, together with cranial base and microsurgical techniques, has allowed neurosurgeons to approach the sinus with reduced morbidity and mortality, changing the natural history of selected lesions. The same study stated that surgical reduction of such lesions enhances the chances for success of subsequent therapy.
A 2007 report on 111 cases treated over 14 years described cavernous sinus meningiomas as particularly challenging because of their deep location and strong adhesion to the sinus, requiring surgical expertise and skills. The authors noted that it is usually difficult to achieve complete removal without significant morbidity or mortality. A 2019 review confirmed that outcomes after surgery remain unsatisfying because of a low total resection rate and a high recurrence rate. The review noted that microsurgical treatment has gradually improved with the development of skull base techniques and surgical approaches, and that newer therapies such as stereotactic radiosurgery, molecular targeting treatment, and comprehensive treatment are also being used.
No drug therapy is mentioned in any of the abstracts. The 2019 review references molecular targeting treatment and comprehensive treatment as emerging approaches, but provides no drug names, no response rates, no survival data, and no sample sizes for any pharmacological intervention. What is still missing are completed clinical trials that test specific molecular agents against cavernous sinus meningioma, adequate patient stratification by tumour biology and location, and funding to move beyond surgical and radiosurgical case series into prospective drug studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Operative Neurosurgery · 2005 · 169 citations
Microsurgical Anatomy and Approaches to the Cavernous Sinus
AbstractOBJECTIVE: The aim of this article is to describe the anatomy of the cavernous sinus and to provide a guide for use when performing surgery in this complex area. Clinical cases are used to illustrate routes to the cavernous sinus and its contents and to demonstrate how the cavernous sinus can be used as a pathway for exposure of deeper structures. METHODS: Thirty cadaveric cavernous sinuses were examined using x3 to x40 magnification after the arteries and veins were injected with colored silicone. Distances between the entrance of the oculomotor and trochlear nerves and the posterior clinoid process were recorded. Stepwise dissections of the cavernous sinuses, performed to demonstrate the intradural and extradural routes, are accompanied by intraoperative photographs of those approaches. RESULTS: The anatomy of the cavernous sinus is complex because of the high density of critically important neural and vascular structures. Selective cases demonstrate how a detailed knowledge of cavernous sinus anatomy can provide for safer surgery with low morbidity. CONCLUSION: A precise understanding of the bony relationships and neurovascular contents of the cavernous sinus, together with the use of cranial base and microsurgical techniques, has allowed neurosurgeons to approach the cavernous sinus with reduced morbidity and mortality, changing the natural history of selected lesions in this region. Complete resection of cavernous sinus meningiomas has proven to be difficult and, in many cases, impossible without causing significant morbidity. However, surgical reduction of such lesions enhances the chances for success of subsequent therapy.
AbstractCavernous sinus meningiomas were once considered unresectable. The development of microsurgical and skull base techniques as well as advances in anesthesia and neuroradiology have allowed safe and systematic treatment of these lesions. Proper evaluation and patient counseling are required. A thorough understanding of the anatomy and surgical approaches are crucial to success, as is knowledge of the possible adverse outcomes including cranial neuropathy and stroke. The authors discuss these issues in the treatment of cavernous sinus meningiomas.
Cavernous Sinus Meningiomas: Surgical Strategies and Outcome in 111 Cases Treated over a Period of 14 Years
AbstractPurpose: Cavernous sinus (CS) meningiomas represent particularly challenging lesions for neurosurgeons because of their deep location and strong adhesion to the sinus thus requiring surgical expertise and skills. Despite that, it's usually difficult to achieve a complete removal of these lesions without significant morbidity and/or mortality. We present our experience in the management of this kind of lesion with particular emphasis to surgical and nonsurgical strategies.
Cavernous Sinus Meningiomas: Surgical Strategies and Outcome in 111 Cases Treated over a Period of 14 Years
AbstractPurpose: Cavernous sinus meningiomas represent particularly challenging lesions for neurosurgeons because of their deep location and strong adhesion to the sinus, thus requiring surgical expertise and skills. Despite that, it's usually difficult to achieve a complete removal of these lesions without significant morbidity and/or mortality. We present our experience in the management of this kind of lesion with particular emphasis on surgical and nonsurgical strategies.
[Progress in the treatment of cavernous sinus meningioma].
AbstractCavernous sinus meningiomas refer to meningiomas primarily originate from the cavernous sinus or meningiomas originate from the anterior clinoid,inner sphenoid ridge and invade into the cavernous sinus.The tumor often invade several structures in the cavernous sinus or parasella region,which makes the resection of tumor a challenge work.The outcomes after surgery are unsatisfying because the low total resection rate and the high recurrence rate.With the development of skull base techniques and surgical approaches,the micro-surgical treatment of the cavernous sinus meningioma is gradually improved.In recent years,new therapies such as stereotactic radiosurgery,molecular targeting treatment,comprehensive treatment are also used to treat cavernous sinus meningioma.In this article,the recent advancements in the treatment of cavernous sinus meningiomas are reviewed.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
